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Angiogenesis describes the growth of new blood 
vessels from preexisting ones and occurs during 
embryonic development and in the female re-
productive cycle. In addition to physiological 
angiogenesis, vessel growth is closely associated 
with the progression of various tumors (Streit 
and Detmar, 2003). More specifically, the onset 
of tumor vascularization, known as angiogenic 
switch, defines progression to a highly malignant 
and eventually metastatic state (Bergers and 
Benjamin, 2003).
The  vascular  endothelial  growth  factor 
(VEGF) is crucial for physiological as well as 
pathological  angiogenesis. VEGF,  binding  to 
the tyrosine kinase receptor VEGFR2 together 
with Nrp1 (neuropilin-1) and VEGFR3, requires 
the concerted interaction with other modu-
lating pathways such as Notch, angiopoietin/
Tie2, and ephrin/Eph to foster functional vessel 
growth (Adams and Alitalo, 2007). In tumors 
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Endothelial Wnt/-catenin signaling is necessary for angiogenesis of the central nervous 
system and blood–brain barrier (BBB) differentiation, but its relevance for glioma vas-
cularization is unknown. In this study, we show that doxycycline-dependent Wnt1 
expression in subcutaneous and intracranial mouse glioma models induced endothelial 
Wnt/-catenin signaling and led to diminished tumor growth, reduced vascular density, 
and normalized vessels with increased mural cell attachment. These findings were cor-
roborated in GL261 glioma cells intracranially transplanted in mice expressing dominant-
active -catenin specifically in the endothelium. Enforced endothelial -catenin 
signaling restored BBB characteristics, whereas inhibition by Dkk1 (Dickkopf-1) had 
opposing effects. By overactivating the Wnt pathway, we induced the Wnt/-catenin–
Dll4/Notch signaling cascade in tumor endothelia, blocking an angiogenic and favoring a 
quiescent vascular phenotype, indicated by induction of stalk cell genes. We show that 
-catenin transcriptional activity directly regulated endothelial expression of platelet-
derived growth factor B (PDGF-B), leading to mural cell recruitment thereby contribut-
ing to vascular quiescence and barrier function. We propose that reinforced 
Wnt/-catenin signaling leads to inhibition of angiogenesis with normalized and less 
permeable vessels, which might prove to be a valuable therapeutic target for antiangio-
genic and edema glioma therapy.
© 2012 Reis et al.  This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months after 
the publication date (see http://www.rupress.org/terms). After six months it is 
available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).
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corroborated these findings. Conversely, Dkk1-expressing   
tumors were bigger with higher vascular density and little   
attachment of SMCs/PCs to ECs.
Mechanistically, we provide evidence that activation of 
the Wnt/-catenin pathway leads to the up-regulation of 
Dll4 (Delta-like 4) and increased Notch signaling in ECs dur-
ing tumor neoangiogenesis. As a consequence of Wnt path-
way activation, expression of tip cell genes was inhibited, 
whereas stalk cell genes were up-regulated, resulting in more 
quiescent ECs. Moreover, we show that transcriptional 
active -catenin regulates the expression of platelet-derived 
growth factor B (PDGF-B) in the tumor endothelium, lead-
ing to increased SMC/PC coverage. In summary, our results 
provide the first evidence that enforced Wnt/-catenin 
signaling reduces tumor angiogenesis on the one hand and 
augments SMC/PC recruitment via PDGF-B induction on 
the other, leading to a normalized glioma vessel phenotype 
with restored barrier properties.
RESULTS
The Wnt/-catenin pathway is active in vessels of human 
glioma but does not correlate with tumor grade
As Wnt/-catenin signaling has been shown to be active in 
vessels of human GBM by staining of nuclear -catenin 
(Yano et al., 2000b), we wanted to evaluate whether gene 
expression of crucial Wnt pathway genes correlates with GBM. 
Analysis via the Texas Cancer Genome Analysis (TCGA) for 
selected Wnt pathway genes revealed up-regulated Wnt5a, a 
noncanonical factor, in human GBM (Fig. 1 A). Canonical 
Wnt factors, of which Wnt1, Wnt3a, and Wnt7a/b have 
been implicated in brain angiogenesis and BBB induction, 
were not regulated compared with normal brain. Interest-
ingly, the soluble Wnt/-catenin inhibitor Dkk1 showed 
in mean an elevation with big variability, whereas Dkk2, 
which  has  been  proposed  to  have  opposing  function  to 
Dkk1 in angiogenesis (Min et al., 2011), showed a contrary 
expression profile.
Staining for -catenin of normal human brain sections 
revealed no nuclear staining of the protein in ECs, con-
firming our own previous results in adult mice (Fig. 1 B; 
Liebner et al., 2008). Compared with normal brain, several 
vessels in the tumor proper showed nuclear -catenin lo-
calization but revealed no correlation with tumor grade 
(Fig. 1 C). However, the function of Wnt/-catenin sig-
naling  in  pathological  angiogenesis  has  not  been  eluci-
dated so far.
Wnt1 reduces subcutaneous glioma growth  
in NMRI-Foxn1nu (NUDE) mice
To study the role of endothelial Wnt/-catenin signaling 
in glioma angiogenesis, we established doxycycline (DOX)-
inducible GL261 mouse glioma cell lines that upon DOX 
removal (DOX) stably express either the empty vector 
(controlD), mouse  Wnt1 (Wnt1D), or human Dkk1 (Dkk1D). 
The induction of Wnt1 or Dkk1 expression was verified by 
Western blotting (Fig. 2 A), and the functional activity of the 
however,  VEGF overexpression downstream of HIF1 (hy-
poxia inducible factor 1 ) drives abnormal vessel growth and 
functions as a vascular permeability factor.
The  WHO  grade  IV  astrocytoma  or  glioblastoma 
(GBM) is one of the most vascularized and deadliest tumors 
(Machein and de Miguel, 2009). Because of its brain loca-
tion, clinicians have to face specific complications such as 
loss of blood–brain barrier (BBB) characteristics in tumor 
vessels, leading to edema formation. Targeting glioma an-
giogenesis by VEGF inhibition had only minor impact on 
patient survival (Brastianos and Batchelor, 2009). Instead, it 
has been proposed that tumor vessel normalization rather 
than  inhibition  of  angiogenesis  is  beneficial  for  tumor 
treatment, leading to reduced interstitial tumor pressure 
and metastasis and increased drug delivery (Carmeliet and 
Jain, 2011).
Beside VEGF, Notch, and other factors, the Wnt path-
way has recently been shown to participate in developmental 
brain angiogenesis and in vascular differentiation to the 
BBB phenotype (Liebner et al., 2008; Stenman et al., 2008; 
Daneman  et  al.,  2009).  Wnts  are  glycosylated  growth 
factors binding to receptors of the frizzled family (Smolich 
et al., 1993; Willert et al., 2003). Depending on the Wnt 
growth factor and the receptor context with Lrp5/6 co-
receptors, signaling differs between the -catenin/Lef/TCF 
(canonical) and the Ca2+/protein kinase C or the planar cell 
polarity pathway (summarized as noncanonical; Chien et al., 
2009). The Wnt/-catenin pathway, which is understood 
best, has been implicated in developmental vasculo- and 
angiogenesis and in this context also in tip/stalk cell deter-
mination as well as in hereditary vascular diseases in humans 
(Franco et al., 2009; Phng and Gerhardt, 2009). In GBM, 
the noncanonical Wnt pathway driven by Wnt5a was shown 
to participate in tumor progression, most likely in a tumor 
cell–autonomous fashion (Kamino et al., 2011; Augustin 
et al., 2012). Although considerable information is available 
on tumor angiogenesis in general and on the role of VEGF 
herein, little is known about the canonical Wnt pathway 
in endothelial cells (ECs) under these conditions (Liebner 
and Plate, 2010).
Interestingly, Yano et al. (2000a,b) observed nuclear local-
ization of -catenin in tumor vessels of induced rat gliomas 
and of human GBM, suggesting a yet unknown involvement 
of endothelial Wnt/-catenin signaling for brain tumor 
angiogenesis, although the function remained obscure. To 
address the function of the endothelial Wnt pathway for 
glioma angiogenesis, we stably transfected the mouse GL261 
glioma cell line with Wnt1 or the soluble Wnt signaling 
inhibitor Dkk1 (Dickkopf-1). Surprisingly, Wnt1-expressing 
tumors were significantly smaller, vascular density was decreased, 
and investment with smooth muscle cells (SMCs) and peri-
cytes (PCs) was augmented. This resulted in normalized and 
quiescent tumor vessels with increased barrier properties, in-
dicated by junctional staining of tight junction (TJ) markers and 
decreased IgG leakage, respectively. A genetic gain-of-function 
(GOF)  mouse  model  for  endothelial  -catenin  transcription JEM Vol. 209, No. 9 
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sized tumors revealed no obvious dif-
ference  between  the  controlD  and 
Wnt1D condition (Fig. 2 E). Nota-
bly, necrotic areas with surrounding 
pseudopalisading cells were observed, 
suggesting that both tumors suffered 
from nutrition and oxygen depriva-
tion. However, Dkk1D tumors were 
rather  compact  with  small  necrotic 
areas (Fig. 2 E).
Hypoxia  is  increased  in  Wnt1- 
compared  with  Dkk1-expressing 
tumors. To evaluate tumor hypoxia, 
mice  bearing  similar  sized  tumors 
were injected with hypoxyprobe-1, 
revealing in controlD and Wnt1D 
tumors pronounced hypoxia with no 
significant  difference.  Dkk1D  tu-
mors  showed  significantly  reduced 
hypoxic  areas  (Fig.  2  F),  matching 
the few necrotic areas evaluated by 
tumor histology (Fig. 2 E). Because 
cell culture experiments showed no 
differences in proliferation (Fig. 2 C), 
cell cycle, and cell death between the three GL261 lines (not 
depicted), we hypothesized that Wnt1 and Dkk1 affect tumor 
vascularization, thus leading to differences in tumor growth. 
Wnt1 and Dkk1 functionally targeted the angiogenic endo-
thelium in vivo, analyzed by nuclear localization of -catenin 
in tumor vessels. Compared with controlsD, the Wnt1D  
tumor endothelium showed a significant increase in nuclear 
-catenin, which is the hallmark of canonical Wnt signaling 
(Fig. 2 G). In contrast, nuclear -catenin was decreased in 
Dkk1D tumor vessels, suggesting that both Wnt1 and Dkk1 
effectively stimulated the tumor endothelium.
Vessel density is decreased, wher2eas vessel stabilization is 
increased in Wnt1-expressing subcutaneous GL261 tumors
To exclude variations between the Wnt1- and Dkk1-expressing 
cell populations and to specifically show the effects of Wnt1 and 
proteins was tested in co-cultures with HEK293 cells trans-
fected with the sTOP/sFOP-FLASH reporter for -catenin 
signaling (Fig. 2 B). Growth of Wnt1-GL261 cells showed 
the highest proliferation followed by Dkk1 and control cells. 
Notably, no growth differences could be observed by DOX 
administration  (Fig.  2  C). A  detailed  characterization  of 
these cell lines did not reveal significant differences in cell 
cycle, cell death, or in the expression of other Wnt ligands, 
including Wnt inhibitory proteins of the secreted frizzled-
related protein family and Dkk family, as well as WIF1 (Wnt 
inhibitory factor-1; not depicted).
To evaluate tumor growth, we subcutaneously trans-
planted the GL261 lines in NUDE mice DOX. During 
20 d of growth, Wnt1D tumors remained smaller, whereas 
Dkk1D tumors were bigger compared with the controls 
(Fig. 2 D). Hematoxylin and eosin (H&E) staining on similar 
Figure 1.  Nuclear -catenin in vessels 
of human astrocytoma does not corre-
late with WHO grade. (A) TCGA database 
analyses for Wnt1, Wnt3a, Wnt5a, Wnt7a, 
Wnt7b, Dkk1, and Dkk2 mRNA expression as 
log2-fold expression. Differences in mRNA 
expression in GBM compared with normal 
central nervous system tissue (dashed red 
line) are shown. (B and C) Paraffin sections 
of three normal human brains (B) and five 
different human astrocytoma WHO grades 
I–IV (C) stained for -catenin and analyzed 
for its endothelial, nuclear localization.  
Insets show individual nuclei in higher  
magnification. Bars: (B) 14 µm; (C) 20 µm.1614 Wnt modulates glioma angiogenesis | Reis et al.
significantly smaller and mouse survival was increased (Fig. 3 A). 
On Dkk1-GL261 tumors, DOX withdrawal (Dkk1D) had 
the opposite effect (Fig. 3 B), confirming the finding of the 
initial comparison between controlD, Wnt1D, and Dkk1D 
Dkk1 release on tumor growth, we repeated the initial sub-
cutaneous  tumor  experiment  with Wnt1-  or  Dkk1-GL261 
lines in the presence or absence of DOX (+D, D). In the 
presence of Wnt1 expression (Wnt1D), GL261 tumors grew 
Figure 2.  Wnt1 expression decreased subcutaneous GL261 tumor growth and increased animal survival. (A) Western blots showing Wnt1  
and Dkk1 expression +/DOX in GL261 cells. (B) sTOP-FLASH assay on human embryonic kidney (HEK293)/GL261 co-cultures without DOX. Monoculture 
of transfected HEK293 cells served as baseline. Wnt1 and Dkk1 cells were cultured without () or with (+) Wnt3aCM (one experiment in triplicate).  
(C) In vitro proliferation of the control-, Wnt1-, and Dkk1-GL261 line cultured +/DOX. (D, left) Representative pictures of NUDE mice with subcutaneous 
tumors DOX. (right) Tumor volumes (n = 7/group) of the transplanted glioma cell lines DOX (*, P < 0.05; **, P < 0.01). (E) H&E-stained paraffin sections 
revealed reduced necrotic areas for Dkk1-expressing tumors (N). (F, left) Pimonidazole (brown) immunohistochemistry staining revealed tumor hypoxia, 
hematoxylin counterstaining (blue). (right) Hypoxia in Dkk1D compared with the controlD (*, P < 0.05) and Wnt1D tumors (**, P < 0.01; n = 4 tumors/
group, slices from the center of similar sized tumors). (G, left) Representative vessels, stained for nuclear -catenin (brown) and hematoxylin (blue) of 
controlD, Wnt1D, and Dkk1D tumors. Arrowheads point to -catenin+ nuclei. (right) Quantification of -catenin+ nuclei (n = 4 tumors/group, 20 vessels/
tumor; ***, P < 0.001). Bars: (D) 1 cm; (E and F) 400 µm; (G) 35 µm. Error bars indicate SEM.JEM Vol. 209, No. 9 
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vessel density was increased (Fig. 3 D). The vessel reduction in 
Wnt1D tumors was accompanied by increased attachment of 
-SMA+ cells (Fig. 3 C). Notably, in Dkk1 tumors in general, 
-SMA+ cells were frequently detached from the tumor en-
dothelium and were regularly detected in the tumor stroma, 
showing no difference upon DOX treatment (Fig. 3 D). From 
the images in Fig. 3 (C and D) it can be deduced that the size 
of tumor vessels was increased in the 
Wnt1D group as compared with the 
Wnt1+D  and  Dkk1+/D  groups  (see 
also Fig. 8 B). To determine function-
ality of tumor blood vessels, mice were 
perfused with isolectin, revealing that 
the majority of vessels from controlD, 
Wnt1D, and Dkk1D tumor groups 
exhibited blood flow (Fig. 3 E). The 
effects of Wnt1 on tumor vascular-
ization and growth in the subcutane-
ous transplantation paradigm could 
be confirmed independently by a C6 
rat glioma cell line stably expressing 
Wnt1 (not depicted).
Antiangiogenic and vessel-
normalizing effect of -catenin 
signaling is EC autonomous
To understand whether Wnt1 and 
Dkk1 have angiogenic effects in a 
tumor cell–free angiogenesis para-
digm, we performed in vivo Matrigel 
tumors (Fig. 2 D) and arguing for a specific, expression- 
dependent effect of Wnt1 and Dkk1.
We investigated tumor vessel density and morphology 
by staining for the endothelial marker CD31/PECAM-1 and 
 smooth muscle actin (-SMA; Fig. 3, C and D). Interest-
ingly, Wnt1D tumors showed decreased vessel density com-
pared with Wnt1+D (Fig. 3 C), whereas in Dkk1D tumors 
Figure 3.  Tumor-derived Wnt1 re-
duced and normalized subcutaneous 
tumor vascularization, whereas Dkk1 
caused the opposite effect. (A) Tumor 
growth in Wnt1D compared with Wnt1+D 
condition (left; n = 12/group; **, P < 0.01; 
***, P < 0.001) and mouse survival (right;  
n = 12/group). (B) Tumor volume for Dkk1D 
compared with Dkk1+D condition (left;  
n = 12/group; *, P < 0.05; **, P < 0.01; ***,  
P < 0.001) and mouse survival of Dkk1+/D  
tumors (right; n = 12/group). (C, top)  
IF staining on subcutaneous Wnt1 tumors 
for CD31/PECAM-1, -SMA, and TOPRO-3. 
(bottom left) Vessel density of subcutane-
ous Wnt1 tumors +/DOX (n = 5 tumors/
group, 10 pictures/tumor; **, P < 0.01). 
(bottom right) Association of -SMA+ cells 
to ECs in Wnt1+/D tumors (n = 5 tumors/
group, 10 vessels/tumor; ***, P < 0.001).  
(D) Same staining and experimental settings 
as in C for subcutaneous Dkk1+/D tumors 
(*, P < 0.05). (C and D) Insets show vessels 
in higher magnification. (E) Perfusion with 
isolectin revealed that vessels from 
controlD, Wnt1D, and Dkk1D tumors 
exhibited blood flow. Bars: (C and D) 400 µm; 
(E) 200 µm. Error bars indicate SEM.1616 Wnt modulates glioma angiogenesis | Reis et al.
we investigated whether endothelial barrier properties are 
affected by modulating the Wnt pathway in experimental 
glioma by staining thick sections of tumor-bearing brains 
for endogenous mouse IgG, which is frequently used as a 
marker for BBB disruption. Confocal imaging and large 
image reconstruction revealed strong IgG leakage into the 
tumor and the surrounding brain parenchyma in controlD 
and Dkk1D glioma, which was substantially reduced in Wnt1D 
tumor-bearing brains (Fig. 5 D). Notably, in controlD and 
Dkk1D brains, IgG was detectable around the lateral ventri-
cles and on the contralateral hemisphere. Instead, for Wnt1D 
tumors this was not observed. Higher magnifications con-
firmed weaker IgG staining also in the immediate circum-
ference of podocalyxin (Podxl)-positive (Podxl+) vessels in 
Wnt1D tumors, suggesting that these vessels retained or 
regained barrier properties (Fig. 5 D).
Endothelial Wnt/-catenin signaling partially rescues  
the loss of BBB junction markers in GL261 glioma vessels
The TJ protein Cldn3 (claudin-3) has previously been shown 
to become down-regulated in several brain pathologies such 
as tumors and inflammation, and it has been identified as a 
Wnt/-catenin target in ECs (Wolburg et al., 2003; Liebner 
et al., 2008). Stainings for Cldn3 together with the endothelial 
marker CD31/PECAM-1 showed that CD31 was localized 
at cell–cell junctions of tumor vessels in the three tumor types 
(Fig. 6 A), whereas Cldn3 showed a punctuate staining only 
occasionally overlapping with the CD31+ areas in controlD 
and Dkk1D tumors. Instead, in Wnt1D tumors more con-
tinuous, junctional staining of Cldn3 that colocalized with 
CD31 was observed, arguing for more elaborate TJs as ob-
served in physiological brain vessels. In tumor vessels of 
Wnt1D glioma, other junctional markers such as Cldn5 and 
ZO-1 (zonula occludens 1) also showed more restricted junc-
tional staining (Fig. 6 B).
Endothelial-specific activation of -catenin signaling 
results in vessel quiescence of intracranial GL261 tumors
We  further  asked  whether  dominant  endothelial-specific   
activation of -catenin signaling can mimic the effects ob-
served in Wnt1-expressing tumors. Therefore, we generated 
mice expressing a dominant-active form of -catenin spe-
cifically in the endothelium (GOF) and intracranially trans-
planted the parental, not engineered GL261 glioma cells. In 
brief, we made use of the Pdgfb-iCreERT2 mice crossed to 
the -cateninExon3flox/flox line as previously described (Liebner 
et al., 2008). The mice were sacrificed when the first animals 
showed symptoms (see Materials and methods). Recombina-
tion was induced by subcutaneously transplanted tamoxifen 
pellets (free base) on the same day of tumor transplantation. 
Recombination of intracranial tumor vessels was evaluated   
by crossing Pdgfb-iCreERT2 and ROSA26STOPfloxLacZ mice. 
Staining for Podxl and -galactosidase revealed endothelial 
recombination of 30% (Fig. 7 A).
In the GOF (Pdgfb-iCreERT2 × -cateninExon3flox/flox + 
tamoxifen) tumors, we observed reduced vessel density compared 
plug assays. For this purpose, Matrigel plugs were supple-
mented with recombinant Wnt1 or Dkk1 protein and in-
jected in C57BL/6 mice, which were sacrificed after 7 d.  Vessel 
density was analyzed by measuring the CD31/PECAM1-
positive (CD31+) area in relation to the plug area. Compared 
with controls, the CD31+ area was decreased in Wnt1 and 
increased in Dkk1 Matrigel plugs, confirming the finding 
in GL261 tumors that Wnt1 decreased and Dkk1 fostered 
angiogenesis (Fig. 4, A and B).
Wnt1 expression leads to quiescent vessels  
and reduces tumor volume and IgG leakage  
in intracranial transplantations
To evaluate orthotopic growth, vascularization, and BBB 
characteristics of glioma vessels, we transplanted the engi-
neered GL261 cell lines into the striatum of NUDE mice 
(Fig. 5 A). Consistent with the subcutaneous tumor experi-
ments, Wnt1D tumors grew the slowest and the volume was 
notably decreased compared with controlsD and even more 
pronounced compared with the Dkk1D glioma (Fig. 5 B).
Vascular density was also significantly reduced in intracranial 
Wnt1D tumors (Fig. 5, A and B). We further characterized 
GL261 glioma vessels for PC coverage by staining for desmin. 
Consistent with the subcutaneous paradigm, the vessels of 
Wnt1D showed significantly augmented attachment of desmin+ 
cells, supporting a normalized vascular morphology (Fig. 5 C).
Wnt/-catenin signaling as well as PCs have been shown 
to be important for the establishment and maintenance of the 
BBB (Armulik et al., 2010; Daneman et al., 2010). Therefore, 
Figure 4.  Tumor cell–free Matrigel plug assay confirmed the anti-
angiogenic effect observed in Wnt1-GL261 tumors. (A) Immuno-
histochemistry staining for CD31/PECAM-1 (red) and hematoxylin 
counterstaining (blue) of Matrigel plug sections, supplemented with dilu-
ent (control), 400 µg/ml human Wnt1, or 200 µg/ml mouse Dkk1 recombi-
nant proteins. Bar, 200 µm. (B) Quantification of CD31+ area in percentage  
in Matrigel plugs (n = 6 plugs/group, 8 representative pictures/plug;  
**, P < 0.001). Error bars indicate SEM.JEM Vol. 209, No. 9 
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increased  desmin+  cells  attached  to 
the endothelium (Fig. 7 D and  Videos 
3 and 4). We next asked for the mech-
anism by which endothelial Wnt/ 
-catenin signaling hampers tumor 
angiogenesis, leading to the quies-
cent and normalized vessel pheno-
type described above.
Wnt/-catenin signaling  
results in Dll4 expression  
and a stalk cell gene signature
The Notch pathway via Notch1/4 
and Dll4 has been shown to be a key 
regulator in vessel sprouting by in-
hibiting the tip cell and promoting 
the stalk cell phenotype (Phng and 
Gerhardt,  2009).  Recently,  Corada   
et al. (2010) could show that -catenin 
signaling regulates Dll4 during early 
embryonic angiogenesis but becomes 
silenced during late embryonic and 
postnatal development.
To understand whether endothe-
lial Wnt/-catenin signaling regulates 
Dll4 also in the tumor endothelium, we performed Dll4 in situ 
hybridization (ISH). Hematoxylin counterstaining revealed   
tumor vessel–specific Dll4 expression in all three tumor condi-
tions (Fig. 8 A). Analysis of vessel diameter revealed significantly 
decreased small and increased big vessels for Wnt1D tumors, as 
opposed to the vascular phenotype in Dkk1D tumors (Fig. 8 B). 
Interestingly, in all tumor conditions small vessels were positive 
for Dll4, which is in line with an endothelial tip cell char-
acteristic described in a previous publication (Hellström et al., 
2007). In this regard, it was apparent that in Wnt1D tumors 
with the controls (Pdgfb-iCreERT2 + tamoxifen; Fig. 7 B). 
Interestingly, the basal lamina of control tumor vessels regu-
larly showed a rough distribution around the endothelium, 
whereas in the GOF condition it had a smooth appearance as 
revealed by collagen IV (ColIV) staining, speaking for a more 
quiescent vessel phenotype (Fig. 7 C and Videos 1 and 2). 
Indeed, ColIV was more closely distributed around the vas-
cular wall in the GOF tumor vessels, as indicated by a 
lower ratio of ColIV to Podxl (Fig. 7 C). The normalized 
vessel phenotype in GOF tumors was further underlined by   
Figure 5.  Tumor-derived Wnt1 nor-
malized vascularization and retained 
vascular barrier properties in GL261 
glioma. (A, left) Representative H&E stain-
ing of serial thick sections of tumor-bearing 
mouse brains. (right) Corresponding IF 
staining for Podxl and TOPRO-3. (B, top) 
Quantification of glioma volume based on 
H&E staining (controlD n = 3, Wnt1D n = 6, 
and Dkk1D n = 4; *, P < 0.05). (bottom) 
Podxl+ vessel areas within tumors (control  
n = 4, Wnt1 n = 6, Dkk1 n = 5; **, P < 0.01). 
(C) IF staining for CD31/PECAM-1 and des-
min (n = 3 tumors/group, 8 pictures/tumor; 
*, P < 0.05). (D) Large image reconstructions 
of IF staining for mouse endogenous IgG 
(mIgG), Podxl, and TOPRO-3 on brain sec-
tions bearing controlD, Wnt1D, and 
Dkk1D glioma. Bars: (A) 200 µm; (C) 50 µm; 
(D, top) 1 mm; (D, bottom) 27 µm. Error bars 
indicate SEM.1618 Wnt modulates glioma angiogenesis | Reis et al.
none of the tested genes were up-
regulated, but NRARP was signifi-
cantly down-regulated.
One of the key pathways to mod-
ulate vascular activation is the angio-
poietin-Tie2 system. In particular, 
ANGPT2 (angiopoietin-2), which is 
highly expressed in angiogenic ECs, 
leads to SMC/PC drop out and vascu-
lar instability (Thomas and Augustin, 
2009). In HUVEC co-cultures, neither 
Wnt1 nor Dkk1 produced by GL261 
cells had a significant effect on endo-
thelial ANGPT2 expression (Fig. 8 C). 
In turn, GL261-derived, murine Angpt1 
was also not regulated in Wnt1D and 
Dkk1D co-culture conditions (not 
depicted). Analysis of total RNA from 
subcutaneous GL261 tumors revealed 
a diminished expression of Angpt2 
specifically in Wnt1D glioma when 
normalized to the endothelial-specific 
gene VE-cadherin, supporting the 
more quiescent phenotype in these 
tumors (not depicted).
To understand the expression of 
Notch  pathway  genes  downstream 
of Wnt/-catenin in more detail, we 
stimulated mouse brain endotheliomas (MBEs) with Wnt3a 
conditioned medium (CM [Wnt3aCM]; Liebner et al., 2008). 
Wnt3aCM robustly induced Axin2 and Dll4 expression as well 
as the Notch targets Hes1 and Hey1 after 18 h of stimulation 
(Fig. 8 D). Jag1, Notch1, and Nrarp were not changed at this 
time point, whereas Flt-1 (VEGFR1), a putative VEGF-A 
decoy receptor, showed significant up-regulation. Other Notch 
targets showed no significant regulation, which was also true 
for arterial genes such as ephrinB2 (not depicted). However, 
after 48 h of stimulation (Fig. 8 D), Jag1 and Notch1 were 
significantly up-regulated, whereas Nrp-1 and Flt4 (VEGFR3) 
were down-regulated.
Transcriptionally active -catenin regulates expression  
of PDGF-B in ECs in vitro
Finally, we intended to clarify the mechanism leading to in-
creased tumor vessel attachment of vascular SMCs/PCs upon 
bigger vessels >300 µm2 were also strongly positive for Dll4, 
which was not the case in controlsD and specifically not in 
Dkk1D tumors (Fig. 8 B).
To test whether GL261-derived Wnt1 directly induces 
Dll4 expression in ECs, we established a co-culture system 
of GL261 cells with human umbilical vein ECs (HUVECs;   
Fig. 8 C). Using human-specific primers, quantitative RT-PCR   
(qRT-PCR) analysis revealed significant up-regulation of   
AXIN2, an endogenous Wnt target gene, and DLL4 in 
Wnt1D/HUVEC compared with controlD/HUVEC co-
cultures, which was not the case in Dkk1D/HUVECs (Fig. 8 C).   
In addition to DLL4, we also observed an up-regulation of 
JAG1 (jagged-1) and of the Notch target NRARP (Notch-
related ankyrin repeat protein), whereas other targets such as 
HES1 (hairy and enhancer of split homologue 1) and HEY (hairy/
enhancer of split related with YRPW motif) were not signifi-
cantly regulated. In Dkk1D co-cultures except for JAG1, 
Figure 6.  Cldn3, Cldn5, and ZO-1 
showed junctional localization in vessels 
of Wnt1-expressing GL261 gliomas.  
(A) IF staining for CD31/PECAM and Cldn3 
on GL261 glioma and normal brain sections. 
Arrowheads indicate junctional localization. 
(B) IF staining for Cldn5 and ZO-1 on cryo-
sections of GL261 brain tumors and normal 
brain. Bars: (A and B, tunors) 33 µm; (A and B, 
normal brain) 10 µm.JEM Vol. 209, No. 9 
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regulation of PDGFB as the best known 
SMC/PC attractant produced by the 
endothelium and observed a significant 
up-regulation  of  PDGFB  messenger 
RNA  (mRNA)  in  the  presence  of 
Wnt1-expressing GL261 cells (Fig. 9 A). 
Comparable results were obtained by 
Wnt3a stimulation of MBEs after 18 
and 48 h (Fig. 9 B).
To understand whether the Pdgfb 
gene is directly regulated by transcrip-
tionally active -catenin, we generated 
EC  lines  derived  from  -catenin–
  deficient  endothelioma  cells  (Cattelino 
et al., 2003), expressing a chimeric con-
struct of Lef1 and the transactivation 
domain of -catenin (LefN-CTA), 
conferring dominant-active transcrip-
tion without affecting the membrane 
function of -catenin or the corre-
sponding  vector  control  (Vleminckx 
et al., 1999). LefN-CTA strongly in-
duced Axin2 as an endogenous reporter 
gene and Pdgfb as indicated by qRT-PCR 
analysis. Western blot analysis revealed 
an up-regulation of PDGF-B and the 
homodimer PDGF-BB by 60%, sug-
gesting that protein translation is also 
taking place (Fig. 9 C).
To further characterize whether Pdgfb expression down-
stream of -catenin transcription is dependent on subsequent 
endothelial Wnt/-catenin activation. As ANGPT2 was not 
significantly regulated upon canonical Wnt pathway activa-
tion in the HUVEC co-culture setting, we investigated the 
Figure 7.  Vascular effects observed in 
Wnt1-expressing gliomas are EC autono-
mous. (A, left) IF staining for -galactosidase 
(-gal), Podxl, and TOPRO-3 on GL261 glioma 
sections from Pdgfb-iCreERT2 × ROSA26STOPfloxLacZ 
mice treated with tamoxifen. (right) Quantifi-
cation of -gal+ vessels. (B, left) IF staining for 
Podxl and TOPRO-3 on GL261 glioma sections 
from Pdgfb-iCreERT2 (control) and Pdgfb-iCre-
ERT2 × CatEx3flox (GOF) mice. (right) Quantifica-
tion of Podxl+ areas within tumors (n = 4 
tumors/group, 10 pictures/tumor; *, P < 0.05). 
(C, left) ColIV and Podxl staining of tumor sec-
tions from control and GOF mice. Arrowheads 
point to nonendothelial-associated ColIV+ 
structures. (right) ColIV/Podxl ratio (n = 4  
tumors/group, 8 pictures/tumor; *, P < 0.05).  
(D, top left) IF staining for CD31/PECAM-1 and 
desmin on tumor sections from control and 
GOF mice (n = 4 tumors/group, 10 pictures/
tumor). (right) Quantification of PC coverage 
(***, P < 0.001). (bottom left) Representative 
vessel in higher magnification (white boxes). 
Bars: (A [left] and D [top]) 160 µm; (A, right)  
40 µm; (B) 400 µm; (C and D [bottom]) 20 µm. 
Error bars indicate SEM.1620 Wnt modulates glioma angiogenesis | Reis et al.
coating,  and  moreover,  blockage  of  the  Notch  pathway  by 
Dll4-Fc had no noticeable effect on Pdgfb, suggesting that its 
regulation by LefN-CTA is Notch signaling independent.
GL261-derived Wnt1 up-regulates expression  
of PDGF-B in ECs in subcutaneous xenografts
To  confirm  the  Pdgfb  mRNA  regulation  by  the  Wnt/ 
-catenin pathway in tumor ECs in vivo, we performed 
ISH from Wnt1-GL261 tumors+/D, showing an increased 
Notch  pathway  activation,  we  analyzed  -catenin–deficient 
cells grown on Dll4-coated dishes or on gelatin as a control 
with and without LefN-CTA expression. In addition, the 
Notch pathway was blocked by a Dll4-Fc fragment (Lobov   
et al., 2007). We could confirm that Dll4 coating induced 
Notch pathway activation as indicated by Hes1 target gene 
expression, which was blocked by supplementation with the 
inhibitory Dll4-Fc peptide (Fig. 9 D). Again, LefN-CTA 
significantly induced Pdgfb mRNA with and without Dll4 
Figure 8.  Glioma-derived Wnt1 up-regulated endothelial Dll4, leading to a stalk cell–like gene signature. (A) ISH against Dll4 (black) 
and hematoxylin (blue) of subcutaneous controlD, Wnt1D, and Dkk1D GL261 tumors, showing representative small (0–300 µm2; left) and large 
(>300 µm2; right) vessels. (B, left) Quantification of vessel diameter (n = 3 tumors/group, 15 pictures/tumor) grouped in categories of 0–30 µm2, 
31–300 µm2, and >300 µm2 (*, P < 0.05; **, P < 0.01). (right) Quantification of Dll4+ ECs (n = 6 tumors/group, 5 small and 5 large vessels/tumor; 
***, P < 0.001). (C, top) HUVECs co-cultivated with controlD, Wnt1D, and Dkk1D GL261 cells (asterisks indicate HUVECs). (bottom) qRT-PCR (n = 6) 
for human genes regulated by Wnt1D and Dkk1D compared with controlD co-cultures (red line). (D) qRT-PCR for mouse genes regulated in 
MBEs stimulated by Wnt3aCM for 18 and 48 h compared with controlCM (red line; n = 3; *, P < 0.05; **, P < 0.01; ***, P < 0.001). Bars: (A) 50 µm;  
(C) 80 µm. Error bars indicate SEM.JEM Vol. 209, No. 9 
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tumor vascularization, leading to decreased and increased   
tumor growth, respectively. These findings were independently 
validated in a subcutaneous C6 rat glioma model constitu-
tively expressing Wnt1 (not depicted). We also provide direct 
evidence that the tumor vasculature is targeted by glioma 
Wnt1, as indicated by increased nuclear -catenin staining as 
the hallmark of -catenin transcription. This finding is of   
particular importance as systemic treatments that activate the 
canonical Wnt pathway do not specifically target the endo-
thelium.  Moreover,  we  show  that Wnt1-driven  -catenin   
signaling did not lead to increased GL261 and C6 tumor 
growth. Along this line, canonical Wnts, as opposed to the 
noncanonical Wnt5a, are not overexpressed in human GBM, 
suggesting that glioma cell–specific -catenin signaling does 
not contribute to glioma initiation and progression. Interest-
ingly, the canonical Wnt pathway has been described as anti-
tumorigenic for glioma cells, making it, in combination   
with the vascular effects we report 
here, an interesting target to be acti-
vated for glioma therapy (Kotliarova 
et al., 2008).
The tumor phenotypes in Wnt1- 
and  Dkk1-expressing  tumors  were 
comparable in the subcutaneous and 
intracranial  transplantation  models 
with some differences regarding ves-
sel size. The latter might be explained 
endothelial-specific signal for Pdgfb upon Wnt1 expression 
(Fig. 10 A). Furthermore, we mechanically isolated tumor 
vessels from Wnt1 tumors+/D (Fig. 10 B). SDS-PAGE and 
Western blot revealed increased PDGF-B protein expression 
in vessels of Wnt1D tumors (Fig. 10 B).
DISCUSSION
The results of our present manuscript provide the first evi-
dence for an antiangiogenic and vessel-normalizing role of 
endothelial Wnt/-catenin signaling in glioma vasculariza-
tion. As tumor vascularization is crucial for the progression 
of various types of malignancies (Saharinen et al., 2011), 
our findings will consolidate the understanding of patho-
logical angiogenesis in general.
Comparing GL261 mouse glioma cells producing either 
Wnt1 or the soluble Wnt inhibitor Dkk1 in a DOX-inducible 
manner, we show that Wnt1 decreased and Dkk1 promoted 
Figure 9.  Pdgfb is a Notch-indepen-
dent target of -catenin signaling  
in ECs. (A) HUVECs co-cultivated with 
controlD, Wnt1D, and Dkk1D GL261  
cells. qRT-PCR (n = 4) for human PDGFB 
regulated by Wnt1D or Dkk1D (ns) com-
pared with controlD (gray line; *, P < 0.05). 
(B) qRT-PCR for Pdgfb gene regulated in 
MBEs stimulated by Wnt3aCM for 18 and 
48 h compared with controlCM (gray line;  
n = 4; *, P < 0.05; ***, P < 0.001). (C, left) 
qRT-PCR for Axin2 and Pdgfb regulated 
in -catenin–deficient ECs transduced 
with LefN-CTA compared with the 
vector control (gray line; n = 4; *, P < 0.05;  
**, P < 0.01). (right) Representative Western 
blot (n = 1) for PDGF-B from LefN-CTA ECs 
compared with the vector control; top band 
shows the nonreduced (PDGF-BB) and bot-
tom band reduced protein (PDGF-B). Densi-
tometric analysis shows the summarized 
values for both forms of PDGF-B of samples 
loaded twice. (D) qRT-PCR of -catenin–
deficient ECs (control) or transduced with 
LefN-CTA grown for 24 h either on  
gelatin- or Dll4-coated dishes (n = 3).  
Notch pathway induction was monitored  
by Hes1 expression (*, P < 0.05; **, P < 0.01). 
Notch signaling was blocked by Dll4-Fc. 
Error bars indicate SEM.1622 Wnt modulates glioma angiogenesis | Reis et al.
on the cross talk of Wnt/-catenin with Dll4/Notch as a 
vessel-stabilizing pathway. In this regard, Corada et al. (2010)  
recently  provided  evidence  for  the  direct,  transcriptional 
control of Dll4 by -catenin signaling during early embry-
onic angiogenesis, leading to a lack of vascular remodeling 
and of venous specification. Interestingly, the authors point 
out that no obvious effects of sustained Wnt/-catenin sig-
naling have been observed after midgestation, despite the fact 
that angiogenic processes were not complete.
In the present manuscript, we show for the first time that in 
pathological glioma angiogenesis, ECs become again respon-
sive  to  the Wnt/-catenin–Dll4  signaling  axis.  Specifically,   
endothelial-specific Dll4 was up-regulated by glioma-derived 
Wnt1, leading to an inhibition of the angiogenic phenotype 
and thus to diminished tumor angiogenesis.
In controlD and in particular in Dkk1D tumors, pre-
dominantly small, angiogenic vessels were Dll4+, supporting 
its role as a tip cell marker (Mailhos et al., 2001; Hellström   
et al., 2007). Interestingly, in Wnt1D tumor vessels, almost all 
ECs showed high Dll4 levels. It is known that Dll4 activates 
Notch signaling in adjacent ECs, influencing the levels of 
VEGFR expression (Hellström et al., 2007; Siekmann and 
Lawson, 2007), namely by lowering levels of VEGFR2 (Williams 
et al., 2006) and Nrp-1 (Gerhardt et al., 2004), thereby deter-
mining stalk cell identity. We show on a molecular level that 
the tip cell receptors VEGFR2/flk1, VEGFR3/flt4, and Nrp1 
were down-regulated and the stalk cell receptor VEGFR1/
flt1 was up-regulated upon Wnt/-catenin signaling, suggest-
ing the induction of a stalk cell–like gene signature. Along this 
by  the  diverging  tumor  microenvironment  that  has  been 
shown by multiple studies comparing subcutaneous versus 
intracranial glioma growth (Arosarena et al., 1994; Blouw et al., 
2003). As hypoxia and subsequent VEGF expression are major 
driving forces of tumor angiogenesis, we investigated the 
three different tumor conditions for hypoxic areas. ControlD 
and Wnt1D subcutaneous tumors showed a similar hypoxic 
status, whereas Dkk1D tumors were almost devoid of hy-
poxia (Fig. 2 F). The finding that Dkk1D tumor vessels 
were functional regarding perfusion suggests that reduced 
hypoxia was a consequence of increased vascularity and 
oxygen supply (Fig. 3 E). As VEGF is a known target of Wnt 
signaling (Zhang et al., 2001), we tested the release of VEGF 
by the three GL261 glioma lines in vitro and observed higher 
levels of VEGF in Wnt1D compared with controlD and 
Dkk1D glioma cells (not depicted).
Surprisingly, Wnt1D tumors showed reduced angiogene-
sis and normalized vessels given that these tumors were as hy-
poxic as the controlsD, likely coinciding with high VEGF-A 
levels. These results suggest that reduced VEGF levels are not 
the cause of quiescent vessels in Wnt1D glioma. Furthermore, 
high VEGF expression in tumors is known to lead to SMC and 
PC drop off and to increase vessel permeability (Olsson et al., 
2006). However, in Wnt1D-GL261 tumors, we observed   
decreased  vascularization  and  an  increased  investment  of   
-SMA+/desmin+ cells, speaking in favor of a diminished re-
sponsiveness of the endothelium to VEGF stimulation.
To mechanistically understand how endothelial Wnt/-
catenin signaling influences VEGF responsiveness, we focused 
Figure 10.  PDGF-B is up-regulated in the tumor endothelium upon Wnt1 expression. (A) Representative ISH for Pdgfb of subcutaneous Wnt1+/D 
tumors. Asterisks indicate vessels, and arrowheads point to Pdgfb+ ECs. Insets show representative vessels in higher magnification. Bars: (full images)  
50 µm; (insets) 18 µm. (B, left) Representative picture of isolated subcutaneous tumor vessels and dot blot for von Willebrand factor (vWF). (right) Repre-
sentative Western blot for PDGF-B with pooled subcutaneous tumors vessels (n = 2 tumors/group). Densitometric analysis for PDGF-B of five indepen-
dent Western blot experiments. Error bars indicate SEM.JEM Vol. 209, No. 9 
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as Cldn3 has been shown to be one of the earliest junction 
proteins at the BBB that is down-regulated under pathologi-
cal conditions (Liebner et al., 2000; Wolburg et al., 2003).
However, the central molecular finding of the present 
manuscript is that we provide the first evidence that the 
SMC/PC-attracting  factor  PDGF-B  is  regulated  down-
stream of Wnt/-catenin signaling in ECs. The regulation 
of PDGFB became apparent in HUVEC co-cultures with 
Wnt1-expressing GL261 cells and in Wnt3a stimulation   
of MBEs, speaking in favor of a direct regulation. Using 
the LefN-CTA dominant-active signaling construct in 
-catenin–deficient ECs, we establish Pdgfb to be directly 
regulated by the canonical Wnt pathway. Neither activa-
tion nor inhibition of Notch signaling in LefN-CTA–
transduced ECs affected Pdgfb up-regulation in vitro. ISH 
and Western blot analysis of tumor vessels corroborated the 
regulation of Pdgfb in Wnt1-expressing tumors contributing 
to SMC/PC recruitment.
The relevance of tumor vessel investment with SMCs/
PCs for vessel normalization and tumor growth is strongly 
supported  by  the  finding  that  PDGF-B–overexpressing 
colorectal tumors exhibit increased mural cell investment, 
normalized vessels, and reduced tumor growth (McCarty   
et al., 2007). Nevertheless, our results provide the first evidence 
for the direct regulation of PDGF-B by Wnt/-catenin in 
ECs, as endothelial-derived PDGF-B is crucial for the proper 
recruitment of PCs (Abramsson et al., 2003).
However, PDGF-B has been proposed to be a tip cell 
marker but at the same time to be important for mural cell 
recruitment to stalk and phalanx cells (Gerhardt et al., 2003). 
Given that Wnt/-catenin signaling has been suggested to 
be predominantly active in stalk cells (Phng et al., 2009), the 
regulation of PDGF-B downstream of -catenin might con-
tribute to the stalk cell behavior and vascular maturation. 
However,  the  exact  mechanism  of  the  cellular  PDGF-B 
regulation in the context of tip and stalk cell identity needs 
further investigation.
Regarding mural cell investment and vessel stabilization, 
we did not observe regulation of human Angpt2 in HUVEC/
GL261 co-cultures (Fig. 8 C). Instead, analysis of total RNA 
from subcutaneous glioma suggested a relative down-regulation 
of Angpt2 in Wnt1D tumors, supporting the observation of 
quiescent tumor vessels (not depicted). This might shift the 
balance toward Angpt1, in turn contributing to the stabilized 
vascular phenotype, as mural cell–derived Angpt1 seems to 
potentiate -catenin signaling in ECs (Zhang et al., 2011).
Regarding  the  protumorigenic  effect  by  Dkk1  over-
expression from GL261 cells, it should be noted that Dkk1 
has effects beyond mere inhibition of Wnt/-catenin. Block-
ing Dll4 in a subcutaneous C6 rat glioma model has been 
shown to result in smaller sized tumors with increased vessel 
density caused by a nonfunctional tumor vascularization 
(Noguera-Troise et al., 2006). Interestingly, in the present 
work,  tumor-derived  Dkk1  resulted  in  hypervascularization   
by functional vessels, as revealed by isolectin perfusion, lead-
ing to reduced hypoxia (Figs. 2 F and 3 E) and thus increased 
line, Jakobsson et al. (2010) showed that the tip cell identity 
is controlled by the relative availability of VEGFR2 and 
VEGFR1, which are downstream of Notch1.
The Notch ligand Jag1 is highly expressed in stalk cells, and 
its overexpression leads to Dll4/Notch1 inhibition and angio-
genic sprouting in a fringe-dependent manner (Benedito et al., 
2009). Interestingly, Jag1 was also significantly up-regulated in 
ECs upon canonical Wnt signaling (Fig. 8, C and D). Although 
Jag1 is a described Wnt target in the hair follicle (Estrach et al., 
2006), our data support the interpretation that Jag1 is not 
directly regulated by -catenin, as Jag1 together with Notch1 
were only induced after 48 h of Wnt3a stimulation, whereas 
direct Wnt targets such as Axin2 and Dll4 were already signifi-
cantly regulated after 18 h (Fig. 8 D). It has also been reported 
that Dll4 coating leads to up-regulation of JAG1 in HUVECs, 
strengthening the interpretation that JAG1 is controlled by 
Notch signaling (Harrington et al., 2008).
Interestingly, we observed a slight but significant up-
regulation of JAG1 in the HUVEC co-culture model with 
Dkk1D GL261 cells, whereas other Notch pathway genes 
remained unchanged. This finding underlines that the relative 
up-regulation of Jag1 compared with Dll4 might foster the an-
giogenic phenotype observed in Dkk1D tumors (Benedito   
et al., 2009).
Segarra et al. (2008) have shown that artificial overex-
pression of Dll4 by BL41 lymphomas leads to reduced angio-
genesis and tumor growth. Li et al. (2007) followed a similar 
approach by overexpressing Dll4 in five different tumor cell 
lines. They also observed a reduction in vessel density and 
increased vessel maturation; however, subcutaneous U87   
human GBM grew significantly bigger compared with the 
controls. This suggests that there is a high degree of cell spec-
ificity for Dll4 concerning tumor cell response, whereas the 
endothelial response is apparently independent of the tumor 
type. Therefore, Dll4 might not be a good primary target in 
GBM but possibly in other malignancies.
Matrigel plug assays showed that the antiangiogenic effect 
of Wnt1 and the proangiogenic effect of Dkk1 are a conse-
quence of endothelial-specific Wnt pathway activation and in-
hibition, respectively. Most relevant, the normalized vascular 
phenotype could be mimicked by endothelial-specific GOF 
for -catenin in intracranial transplanted, parental GL261 
glioma cells. Specifically, endothelial activation of -catenin 
signaling (a) reduced tumor vessel density, (b) led to smooth 
deposition of ColIV to the vessel wall, and (c) resulted   
in thinner, more regular-shaped vessels and (d) increased 
vessel investment by PCs.
The latter have been shown to be important for vessel 
stability and barrier function in the brain (Armulik et al., 
2010; Daneman et al., 2010). Consistently, we could show 
that permeability for endogenous mouse IgG was consider-
ably lower in Wnt1D compared with Dkk1D or controlD 
glioma. In accordance with our previously described role of 
Wnt/-catenin for BBB development (Liebner et al., 2008), 
we observed a partial rescue of junction protein localization 
in Wnt1-expressing tumors. This was even more remarkable, 1624 Wnt modulates glioma angiogenesis | Reis et al.
hygromycin B and cultivated in the presence of 1 µg/ml DOX. HUVECs were 
gifts from M. Tjwa (University Hospital Frankfurt, Frankfurt, Germany). MBEs 
were isolated, transformed with polyoma middle T, and cultivated as previously 
described (Liebner et al., 2008). -Catenin–deficient endothelioma cells were 
generated and cultivated as previously described (Cattelino et al., 2003). Retro-
viral infection with LefN-CTA subcloned in pBABE-puro was performed   
according to standard procedures (Liebner et al., 2004), and infected cells were 
selected by 4-µg/ml puromycin treatment for two splittings. As a vector control, 
the same parental -catenin–deficient cell line was infected with the empty 
pBABE-puro vector, and cells were selected for puromycin resistance as described 
previously (Liebner et al., 2004).
Cell growth curve. 15 × 103 tumor cells were seeded in 24-well plates in 
the presence of DOX. After 24 h, medium was replaced by starving medium 
containing 1% BSA instead of 10% FCS. Again 24 h later, medium was 
changed with normal growth media selectively containing DOX. Living cells 
were identified by 0.04% Trypan blue solution (Sigma-Aldrich) and counted 
in a Neubauer chamber.
Reagents. Tamoxifen (free base) pellets (2 mg, 21-d release) were purchased 
from Innovative Research of America, Matrigel basement membrane matrix 
from BD, Heparin-Natrium 25000 from Ratiopharm, and bFGF from R&D 
Systems.  Recombinant  proteins  were  as  follows:  human Wnt1  (PeproTech), 
mouse Dkk1 as well as human Dll4 (R&D Systems), and Dll4 (mouse):Fc   
(human; rec.; AdipoGen). BCA Protein Assay kit was purchased from Thermo 
Fisher Scientific. Plasmids used were as follows: pTet-Off, pTRE2hyg, and 
pTRE2hyg-Luc (Takara Bio Inc.); pRL-TK (Promega); and pOTB7-human 
Dkk1 (IRAUp969H0447) and pYX-Asc-mouse Dll4 (IRAVp968E10130D; 
imaGenes). pcDNA3-mouse Wnt1 was a gift from G. Cossu (DIBIT San Raffaele 
Scientific Institute, Milan, Italy). Super(8×)TOP-FLASH and super(8×)FOP-
FLASH were provided by R. Moon (University of Washington School of Medi-
cine, Seattle, WA). ChromoMap red was purchased from VENTANA Medical 
Systems Inc. Monoclonal mouse antibodies used were as follows: anti–-catenin 
clone14/-catenin (BD), anti–-SMA clone 1A4 Cy3-conjugated and anti– 
-tubulin clone DM1A (Sigma-Aldrich), antipimonidazole FITC MaB 4.3.11.3 
(NPI Inc.), anti-FITC MaB045P Ms X Fluor HRP (EMD Millipore), and rat 
anti–mouse CD31 (BD and Dianaova). Polyclonal antibodies used were as fol-
lows: rabbit anti–-galactosidase (MP Biomedicals), rabbit anti-Clnd3 (Invitro-
gen), rabbit anti-ColIV (AbD Serotec), rabbit anti–PDGF-B (AB Biotec), and 
goat anti–human Dkk1, goat anti–mouse Podxl, and goat anti–mouse Wnt1 
(R&D Systems). Secondary antibodies used were as follows: appropriated anti-
bodies, streptavidin conjugates, and Alexa Fluor 488 and 568 conjugates (Invitro-
gen). For mouse IgG staining, a goat anti–mouse Alexa Fluor 488 antibody was 
used (Invitrogen). Mouse food containing 100 mg/kg DOX and control food 
was purchased from ssniff Spezialdiäten GmbH.
Luciferase reporter assay. To reveal canonical Wnt signaling, HEK293 cells 
were  transfected  with  super(8×)TOP-FLASH  or  super(8×)FOP-FLASH. 
Firefly luciferase activity was normalized to Renilla luciferase by cotransfec-
tion with pRL-TK plasmid. All measurements were performed in a Lumat 
LB 9507 luminometer (Berthold Technologies).
qRT-PCR. Primers used for qRT-PCR are listed in Tables S1 and S2. RNA 
from cells was isolated with the RNeasy Mini kit from QIAGEN. qRT-PCR 
was performed as previously described (Schneider et al., 2010). For qRT-
PCR analysis on HUVECs, G6pd1 and -actin were used as human refer-
ence genes for normalization. qRT-PCR results are shown from at least three 
independent experiments (specified in figure legends).
Western blot analysis. For GL261 glioma cell analysis, 4 × 105 cells were 
cultured for 2 d in media supplemented either with or without DOX. Cells 
were harvested for Western blot analysis. Western blot was performed as pre-
viously described (Devraj et al., 2009; Schneider et al., 2010). In brief, ECs 
were harvested in 10 mM Hepes, 1 mM EDTA, and 250 mM sucrose plus 
protease inhibitor cocktail with final pH 7.4 (HES + PI), followed by mild 
sonication. Subsequently, BCA assay was performed and samples were stored 
tumor growth. There is emerging evidence that Dkk1 drives 
mobilization  and  the  angiogenic  potential  of  endothelial 
precursor cells (Aicher et al., 2008; Smadja et al., 2010). 
Here we corroborate these data in a mouse glioma model, 
underlining  a  proangiogenic  role  of  Dkk1.  It  should  be 
noted that Min et al. (2011) proposed opposing function of 
Dkk1 and Dkk2, suggesting that Dkk1 confers anti- and 
Dkk2 proangiogenic properties. The apparent discrepancies 
between the data described by Min et al. (2011) and our 
data, which are in line with the data by Aicher et al. (2008) 
and Smadja et al. (2010), might be a result of the different 
experimental settings in vivo and in vitro. It should be noted 
that expression analysis of Dkk1 and Dkk2 in highly angio-
genic human GBM supports a proangiogenic function of 
Dkk1,  as  it  is  up-regulated  and  Dkk2  is  down-regulated 
compared with normal brain tissue (Fig. 1 A; Zhou et al., 
2010). To conclusively describe the function of Dkk1 in an-
giogenesis, additional work needs to be done.
In summary, we demonstrate that continuously elevated 
Wnt/-catenin signaling leads to the initial induction of 
Dll4 and Pdgfb, followed by the acquisition of a stalk cell–
specific gene signature downstream of elevated Notch sig-
naling. Our findings might have multiple consequences for 
GBM therapy: (a) physiological levels of Wnt/-catenin sig-
naling are associated with angiogenesis and stalk cell pro-
liferation, and (b) reinforced and sustained signaling leads 
to reduced angiogenesis independently of VEGF levels, with 
concomitant vessel normalization via Dll4 and PDGF-B 
expression, as well as junctional stabilization. As a conse-
quence of the latter, endothelial Wnt/-catenin partially 
rescues BBB disruption and prevents vasogenic edema. Col-
lectively, these findings make the Wnt/-catenin pathway 
an interesting target that could be exploited for antiangio-
genic and/or antiedema therapy particularly in GBM but 
potentially also in other angiogenic tumors in the periphery 
such as melanoma (Lucero et al., 2010).
MATERIALS AND METHODS
Human GBM specimens. Biopsies of human glioma were provided by the 
University Cancer Center, Goethe University Frankfurt via M. Mittelbronn and 
P.N. Harter. We investigated five cases for each WHO grade I–IV of human gli-
oma biopsies embedded in paraffin. Histological examination was performed by 
at least two experienced neuropathologists (M. Mittelbronn and P.N. Harter). 
Gene expression signatures were analyzed in 424 primary GBMs and 11 normal 
brain samples by assessing the TCGA data portal that used the 244K G4502A 
microarray  (Agilent Technologies)  to  determine  mRNA  profiles  for Wnt1, 
Wnt3a, Wnt5a, Wnt7a, Wnt7b, Dkk1, and Dkk2 to correlate the expression to 
normal brain (https://tcga-data.nci.nih.gov/tcga/tcgaHome2.jsp, accessed 2012 
March 30; Cancer Genome Atlas Research Network, 2008). The raw data for the 
selected genes were downloaded and analyzed in Prism (GraphPad Software) to 
generate scatter blots. Utilization of all human specimens was in accordance with 
the ethics commissions of the Goethe University Clinic Frankfurt, Germany.
Cells. GL261 cells cultivated in D-MEM Media-GlutaMAX-I (Invitrogen) 
containing 10% FCS were stably transfected with pTet-Off plasmid using Trans-
Pass D1 Transfection Reagent (New England Biolabs, Inc.) and selected with   
400 µg/ml G418. Tet-Off–responsive single cell clones were selected for stable 
transfection with the empty vector pTRE2hyg (control) or the vector containing   
either murine Wnt1 or human Dkk1 cDNA. Cells were selected with 200 µg/ml JEM Vol. 209, No. 9 
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slice was evaluated with an Axiophot microscope (Carl Zeiss) with a motor-
ized stage, equipped with a Hitachi HV-C20A camera and the Stereo Inves-
tigator 4.3.4 software (MicrcoBrightField, Inc.). The following formula was 
used to calculate brain tumor volume: tumor volume = slice size (40 µm) × 
step size between the slices (12) × sum of tumor areas from one tube.
Matrigel plug assay. 1 ml Matrigel basement membrane matrix was mixed 
with 30 U Heparin-Natrium 25000, and 1 µg bFGF and supplemented either 
with 400 µg human Wnt1 or 200 µg mouse Dkk1 recombinant protein or with 
an equivalent volume of PBS with 0.1% BSA (control). 500 µl Matrigel mixture 
was injected subcutaneously into 6–8-wk-old C57BL/6 mice. After 7 d, plugs 
were excised, fixed overnight in 10% formaldehyde, and embedded in paraffin.
Immunohistochemical  and  immunofluorescence  (IF)  analysis. H&E 
staining was performed on paraffin sections or 40-µm brain thick sections. Matri-
gel paraffin sections were stained for CD31/PECAM-1 in a  VENTANA Discov-
ery XT staining device. IF staining was either performed on 4% PFA fixed 
cryosections (12 µm) or brain thick sections (40 µm). For staining of Cldn3, 
Cldn5, and ZO-1, 10-µm brain cryosections were fixed with 95% ethanol for 
5 min at 4°C followed by acetone incubation for 1 min at room temperature. 
Light and IF microscopic images were observed either with an 80i microscope 
and documented with a digital DS-5Mc camera or with a C1si confocal micro-
scope (Nikon). Images were computer processed in ImageJ (National Institutes 
of Health) and Photoshop CS4 for Macintosh (Adobe). Vessel density, vessel size, 
and hypoxic areas were determined with NIS Elements AR Imaging Software 
(Nikon). ISH against mouse Dll4 and mouse Pdgfb (provided by H. Gerhardt, 
Cancer Research UK, London, England, UK) was performed on subcutaneous 
paraffin tumor slices as previously described (Schneider et al., 2010).
GL261/HUVEC co-culture experiment. 8 × 105 control-, Wnt1-, and 
Dkk1-GL261 cells were cultivated for 2 d on 0.1% gelatin–coated 60-mm 
dishes. 6 × 105 HUVECs were seeded on the tumor cells, and RNA was 
harvested after 24 h.
Stimulation of MBEs. 3 × 105 MBEs were seeded on 0.1% gelatin-coated   
6-well plates. Control or Wnt3aCM derived from L cells was diluted 1:1 with 
EC growth medium (Liebner et al., 2008). RNA was harvested after 18 h and 
48 h of stimulation, respectively.
Dll4 stimulation and inhibition of Notch signaling. 4 × 105 -catenin–
deficient ECs transduced with either pBABE-puro/LefN-CTA or the 
control vector were seeded on 0.1% gelatin-coated 6-well plates containing   
500 ng/ml human recombinant Dll4 for the stimulation condition. To inhibit 
Notch signaling, 5 µg/ml Dll4 (mouse):FC (human; rec.) was added when seed-
ing the cells (Lobov et al., 2011). RNA was harvested after 24 h of cultivation.
Statistical analysis. Results are shown as the mean ± SEM. A two-tailed, un-
paired Student’s t test for pairwise comparison was used (Prism version 5.0a; 
GraphPad Software). P-values <0.05 were considered significant (***, <0.001; 
**, 0.001–0.01; *, 0.01–0.05).
Online supplemental material. Videos 1 and 2 show the distribution of   
ColIV around the Podxl+ vessel in intracranial control and -catenin GOF 
tumors, respectively. Videos 3 and 4 show the attachment of desmin+ PCs 
around the CD31+ vessel in intracranial control and -catenin GOF tumors, 
respectively. Tables S1 and S2 provide mouse and human qRT-PCR primer 
sequences, respectively. Online supplemental material is available at http://
www.jem.org/cgi/content/full/jem.20111580/DC1.
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at 20°C. For Western blot, a buffer containing 2.3 M urea, 1.5% SDS,   
15 mM Tris, 100 mM DTT, and 0.01% BPB (final concentrations) was added 
to the samples, and proteins were solubilized for 2 h at room temperature 
followed by SDS-PAGE.
The gels were then transferred by standard submerged method, followed 
by Western blotting for the indicated antibodies. The blots were visualized with 
the aid of an enhanced chemiluminescence kit, digitized into film images using 
an AlphaEase FC Imaging System (Alpha Innotech), and the densitometric 
images were then analyzed using Multi Gauge software 3.0 (Fujifilm). Quanti-
tation was performed from 8-bit linear TIF images by selecting equal area from 
each sample lane that encompassed the band of interest and gray values 
obtained after subtracting the background from an empty lane. Densitometric 
measurement was performed on three separated blots for PDGF-B, normalized 
to -tubulin, and shown as relative amounts in percentages.
Tumor experiments. All animal experiments were performed in accordance 
with the German Legislation on the Protections of Animals and the Guide for 
the Care and Use of Laboratory Animals with permission of the Regierungsprä-
sidium Darmstadt (approval no. F94/10). Mice were anesthetized by i.p. injection 
of Ketamine/Xylazine, and 106 cells were implanted subcutaneously into the 
flanks of 6–8-wk-old female NUDE mice. Tumor volume was calculated by the 
formula /6 × (diammax × diammin^2; Yoshio-Hoshino et al., 2007). Mice were 
sacrificed when a tumor diameter of 1.5 cm was reached. For DOX-dependent 
tumor experiments, mice were fed with DOX-containing food 2 wk before 
tumor cell transplantations. The DOX-containing diet was continued during 
tumor growth. Vessel isolation from subcutaneous tumors was performed as 
previously described for brain vessels, but omitting the dextran separation step 
(Fisher et al., 2007). For intracranial tumor transplantations, mice were inserted 
into a stereotactic device, and 105 cells (living cell number) in 2 µl PBS were in-
jected into the striatum using the coordinates relative to bregma: 0.5 (anterior–
posterior), 2 (mediolateral), and 3.5 (dorsoventral). Mice were sacrificed at once 
when showing symptoms. For -catenin activation in vivo, Pdgfb-iCreERT2 
(Claxton et al., 2008) lines were crossed to mice harboring floxed alleles of the 
-catenin exon 3 to obtain homozygous -cateninExon3flox/flox mice (Harada   
et al., 1999), of which 50% also carried one Pdgfb-iCreERT2 allele. After intra-
cranial transplantation of unmodified (parental) GL261 cells, a tamoxifen pellet 
was subcutaneously transplanted in the neck region of each mouse. Single trans-
genic Pdgfb-iCreERT2 heterozygous mice were treated in the same manner.
Tumor hypoxia detection and preparation of tumor material. To de-
tect tumor hypoxia, 60 µg Hypoxyprobe per gram was injected i.p. 30 min be-
fore mice were sacrificed. Subcutaneous tumors were incubated overnight in 
4% PFA, and one half was embedded in paraffin and the other half was infil-
trated with 18% sucrose solution at 4°C overnight and embedded in O.C.T. 
Compound for cryosections. For intracranial tumors, brains were removed, 
incubated in 4% PFA at 4°C overnight, transferred into 0.1 M sodium phosphate 
buffer, pH 7.4, containing 30% sucrose, and incubated for several days at 4°C 
until complete infiltration and directly used to prepare thick sections (40 µm).
Tumor vessel perfusion experiments. 100 µg of biotinylated isolectin 
(Linaris) was administered retrobulbarily after mouse anesthesia 4 min before 
mice were perfused with 4% PFA. Subcutaneous tumors were divided in two 
halves, incubated overnight in 4% PFA, infiltrated with 18% sucrose solution 
at 4°C overnight, and embedded in O.C.T. Compound for cryosections.
Brain tumor volume calculation. Mouse brains containing intracranial 
tumors were harvested and used for sectioning after 30% sucrose buffer infil-
tration. For each brain, a row of 12 Eppendorf tubes was filled with cryopro-
tection solution (two parts 0.1 M sodium phosphate buffer, pH 7.4, mixed 
with one part ethylene glycol and one part glycerin). Serial thick sections (40 µm)   
starting from the olfactory bulb to the cerebellum were performed. Every 
brain slice was consecutively placed in one Eppendorf tube starting with 
tube 1 and ending with tube 12. This procedure was repeated until the 
whole brain was cut. For brain tumor volume calculation, the brain slices of 
one tube were transferred on slides for H&E staining. Tumor area of every 1626 Wnt modulates glioma angiogenesis | Reis et al.
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